X hits on this document

Word document

The usefulness and use of second-generation - page 57 / 81





57 / 81

214 Huber MT, Gotthardt U, Schreiber W, Krieg JC. Efficacy and safety of the sigma receptor ligand EMD 57445 (panamesine) in patients with schizophrenia: an open clinical trial. Pharmacopsychiatry 1999; 32:68-72.

215 Modell S, Naber D, Holzbach R. Efficacy and safety of an opiate sigma-receptor antagonist (SL 82.0715) in schizophrenic patients with negative symptoms: an open dose-range study. Pharmacopsychiatry 1996; 29:63-66.

216 Wolkowitz OM, Pickar D. Benzodiazepines in the treatment of schizophrenia: a review and reappraisal. Am J Psychiatry 1991; 148:714-726.

217 Wassef AA, Dott SG, Harris A, et al. Critical review of GABA-ergic drugs in the treatment of schizophrenia. J Clin Psychopharmacol 1999; 19:222-232.

218Warner R, Laugharne J, Peet M, et al. Retinal function as a marker for cell membrane omega-3 fatty acid depletion in schizophrenia: a pilot study. Biol Psychiatry 1999; 45:1138-1142.

219 Horrobin DF, Glen AI, Vaddadi K. The membrane hypothesis of schizophrenia. Schizophr Res 1994; 13:195-207.

220 Shah S, Vankar GK, Telang SD, et al. Eicosapentaenoic acid as an adjunct in the treatment of schizophrenia. Schizophren Res 1998; 29:158.

221 Puri BK, Richardson AJ. Sustained remission of positive and negative symptoms of schizophrenia following treatment with eicosapentaenoic acid. Arch Gen Psychiatry 1998; 55:188-189.

222 Fenton WS, Dickerson F, Boronow J, et al. A placebo-controlled trial of omega-3 fatty acid (ethyl eicosapentaenoic acid) supplementation for residual symptoms and cognitive impairment in schizophrenia. Am J Psychiatry 2001; 158:2071-2074.

223 Emsley R, Myburgh C, Oosthuizen P, van Rensburg SJ. Randomized, placebo-controlled study of ethyl-eicosapentaenoic acid as supplemental treatment in schizophrenia. Am J Psychiatry 2002; 159:1596-1598.

224 Wilkinson LS. The nature of interactions involving prefrontal and striatal dopamine systems. J Psychopharmacol 1997; 11:143-150.

225 Tamminga CA, Schaffer MH, Smith RC, Davis JM. Schizophrenic symptoms improve with apomorphine. Science 1978; 200:567-568.

Document info
Document views339
Page views339
Page last viewedWed Jan 25 02:49:43 UTC 2017